Skip to main content

Articles

Page 4 of 33

  1. Authors: Andreas Giannisis, Asma Al-Grety, Henrik Carlsson, Jennifer C. Howell, William T. Hu, Kim Kultima and Henrietta M. Nielsen
    Citation: Alzheimer's Research & Therapy 2023 15:160

    The original article was published in Alzheimer's Research & Therapy 2023 15:119

  2. Although increasing physical activity (PA) has been suggested to prevent and manage cognitive decline and dementia, its economic impact on healthcare systems and society is largely unknown. This study aimed to...

    Authors: Weixin Li, Kun-Woo Rafael Kim, Donglan Zhang, Bian Liu, Christine M. Dengler-Crish, Ming Wen, Lu Shi, Xi Pan, Yian Gu and Yan Li
    Citation: Alzheimer's Research & Therapy 2023 15:159
  3. People with mild cognitive impairment (MCI) experience a loss of cognitive functions, whose mechanism is characterized by aberrant structure‒function (SC-FC) coupling and topological attributes of multiple net...

    Authors: Jingsong Wu, Youze He, Shengxiang Liang, Zhizhen Liu, Jia Huang, Weilin Liu, Jing Tao, Lidian Chen, Chetwyn C. H. Chan and Tatia M. C. Lee
    Citation: Alzheimer's Research & Therapy 2023 15:158
  4. Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer’s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences be...

    Authors: Nidhi S. Mundada, Julio C. Rojas, Lawren Vandevrede, Elisabeth H. Thijssen, Leonardo Iaccarino, Obiora C. Okoye, Ranjani Shankar, David N. Soleimani-Meigooni, Argentina L. Lago, Bruce L. Miller, Charlotte E. Teunissen, Hillary Heuer, Howie J. Rosen, Jeffrey L. Dage, William J. Jagust, Gil D. Rabinovici…
    Citation: Alzheimer's Research & Therapy 2023 15:157
  5. Neuron-derived extracellular vesicles (NDEVs) in blood may be used to derive biomarkers for the effects of exercise in Alzheimer’s disease (AD). For this purpose, we studied changes in neuroprotective proteins...

    Authors: Francheska Delgado-Peraza, Carlos Nogueras-Ortiz, Anja Hviid Simonsen, De’Larrian DeAnté Knight, Pamela J. Yao, Edward J. Goetzl, Camilla Steen Jensen, Peter Høgh, Hanne Gottrup, Karsten Vestergaard, Steen Gregers Hasselbalch and Dimitrios Kapogiannis
    Citation: Alzheimer's Research & Therapy 2023 15:156

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:18

  6. Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...

    Authors: Daniele Altomare, Alberto Benussi, Valentina Cantoni, Enrico Premi, Jasmine Rivolta, Chiara Cupidi, Alessandro Martorana, Emiliano Santarnecchi, Alessandro Padovani, Giacomo Koch and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2023 15:155
  7. Preclinical studies highlight the importance of endogenous cannabinoids (endocannabinoids; eCBs) in neurodegeneration. Yet, prior observational studies focused on limited outcome measures and assessed only few...

    Authors: Shiraz Vered, Alexa S. Beiser, Liron Sulimani, Sharon Sznitman, Mitzi M. Gonzales, Hugo J. Aparicio, Charles DeCarli, Matthew R. Scott, Saptaparni Ghosh, Gil M. Lewitus, David Meiri, Sudha Seshadri and Galit Weinstein
    Citation: Alzheimer's Research & Therapy 2023 15:154
  8. Depression and dementia are both common diseases. Although new cases of depression are more common in younger adults, there is a second peak at the age of 50 years suggesting a different pathological process. ...

    Authors: Lindsey I. Sinclair, Asher Mohr, Mizuki Morisaki, Martin Edmondson, Selina Chan, A. Bone-Connaughton, Gustavo Turecki and Seth Love
    Citation: Alzheimer's Research & Therapy 2023 15:153

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:33

  9. The relationship of glucosamine use with incident dementia in the older population remains uncertain. We aimed to evaluate the longitudinal association between habitual glucosamine supplement and the risk of c...

    Authors: Chun Zhou, Yanjun Zhang, Sisi Yang, Ziliang Ye, Qimeng Wu, Mengyi Liu, Panpan He, Yuanyuan Zhang and Xianhui Qin
    Citation: Alzheimer's Research & Therapy 2023 15:152
  10. Rapid-eye movement (REM) sleep highly depends on the activity of cholinergic basal forebrain (BF) neurons and is reduced in Alzheimer’s disease. Here, we investigated the associations between the volume of BF ...

    Authors: Claire André, Marie-Ève Martineau-Dussault, Véronique Daneault, Hélène Blais, Sonia Frenette, Dominique Lorrain, Carol Hudon, Célyne Bastien, Dominique Petit, Alexandre Lafrenière, Cynthia Thompson, Jacques Montplaisir, Nadia Gosselin and Julie Carrier
    Citation: Alzheimer's Research & Therapy 2023 15:151
  11. The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (C...

    Authors: Giuseppe Mario Bentivenga, Simone Baiardi, Andrea Mastrangelo, Corrado Zenesini, Angela Mammana, Barbara Polischi, Sabina Capellari and Piero Parchi
    Citation: Alzheimer's Research & Therapy 2023 15:150
  12. Plasma biomarkers have emerged as promising screening tools for Alzheimer’s disease (AD) because of their potential to detect amyloid β (Aβ) accumulation in the brain. One such candidate is the plasma Aβ42/40 ...

    Authors: Shogyoku Bun, Daisuke Ito, Toshiki Tezuka, Masahito Kubota, Ryo Ueda, Keisuke Takahata, Sho Moriguchi, Shin Kurose, Yuki Momota, Natsumi Suzuki, Ayaka Morimoto, Yuka Hoshino, Morinobu Seki, Yu Mimura, Ryo Shikimoto, Yasuharu Yamamoto…
    Citation: Alzheimer's Research & Therapy 2023 15:149
  13. A minimally invasive blood-based assessment of cognitive function could be a promising screening strategy to identify high-risk groups for the incidence of Alzheimer’s disease.

    Authors: Kanika Mehta, Mohammadreza Mohebbi, Julie A. Pasco, Lana J. Williams, Sophia X. Sui, Ken Walder, Boon Lung Ng and Veer Bala Gupta
    Citation: Alzheimer's Research & Therapy 2023 15:148
  14. Post-stroke cognitive impairment (PSCI) occurs in up to 50% of patients with acute ischemic stroke (AIS). Thus, the prediction of cognitive outcomes in AIS may be useful for treatment decisions. This PSCI coho...

    Authors: Minwoo Lee, Na-Young Yeo, Hyo-Jeong Ahn, Jae-Sung Lim, Yerim Kim, Sang-Hwa Lee, Mi Sun Oh, Byung-Chul Lee, Kyung-Ho Yu and Chulho Kim
    Citation: Alzheimer's Research & Therapy 2023 15:147
  15. Polygenic Risk Scores (PRSs) are summaries of genetic risk alleles for an outcome.

    Authors: Tamar Sofer, Nuzulul Kurniansyah, Einat Granot-Hershkovitz, Matthew O. Goodman, Wassim Tarraf, Iris Broce, Richard B. Lipton, Martha Daviglus, Melissa Lamar, Sylvia Wassertheil-Smoller, Jianwen Cai, Charles S. DeCarli, Hector M. Gonzalez and Myriam Fornage
    Citation: Alzheimer's Research & Therapy 2023 15:146
  16. The Rey Complex Figure Test (RCFT) has been widely used to evaluate the neurocognitive functions in various clinical groups with a broad range of ages. However, despite its usefulness, the scoring method is as...

    Authors: Jun Young Park, Eun Hyun Seo, Hyung-Jun Yoon, Sungho Won and Kun Ho Lee
    Citation: Alzheimer's Research & Therapy 2023 15:145
  17. Despite the high sensitivity of cerebrospinal fluid (CSF) amyloid beta (Aβ)42 to detect amyloid pathology, the Aβ42/Aβ40 ratio (amyR) better estimates amyloid load, with higher specificity for Alzheimer’s disease...

    Authors: Caterina Motta, Martina Gaia Di Donna, Chiara Giuseppina Bonomi, Martina Assogna, Agostino Chiaravalloti, Nicola Biagio Mercuri, Giacomo Koch and Alessandro Martorana
    Citation: Alzheimer's Research & Therapy 2023 15:144
  18. Little is known about the associations of midlife- and late life-initiated walking with Alzheimer’s disease (AD)-related cognitive decline in humans. We aimed to investigate whether high-intensity, prolonged, ...

    Authors: Young Min Choe, Guk-Hee Suh, Boung Chul Lee, Ihn-Geun Choi, Hyun Soo Kim, Jong Wan Kim, Jaeuk Hwang, Dahyun Yi and Jee Wook Kim
    Citation: Alzheimer's Research & Therapy 2023 15:143
  19. Studies in animal models of Alzheimer’s disease (AD) have provided valuable insights into the molecular and cellular processes underlying neuronal network dysfunction. Whether and how AD-related neurophysiolog...

    Authors: Fran C. van Heusden, Anne M. van Nifterick, Bryan C. Souza, Arthur S. C. França, Ilse M. Nauta, Cornelis J. Stam, Philip Scheltens, August B. Smit, Alida A. Gouw and Ronald E. van Kesteren
    Citation: Alzheimer's Research & Therapy 2023 15:142
  20. The effects of insulin-like growth factor-1 (IGF-1) deficiency on cognitive decline have been consistently reported in animal studies, but the relationship between IGF-1 and human brain health remains controve...

    Authors: Zhi Cao, Jiahao Min, Qilong Tan, Keyi Si, Hongxi Yang and Chenjie Xu
    Citation: Alzheimer's Research & Therapy 2023 15:140
  21. Associations between kidney function and dementia risk are inconclusive. Chronic kidney disease (CKD) severity is determined by levels of both estimated glomerular filtration rate (eGFR) and the urine albumin ...

    Authors: Tian-Shin Yeh, Lei Clifton, Jennifer A. Collister, Xiaonan Liu, David J. Hunter and Thomas J. Littlejohns
    Citation: Alzheimer's Research & Therapy 2023 15:138
  22. Alzheimer’s disease (AD) is an age-related disease characterized by altered cognition, neuroinflammation, and neurodegeneration against which there is presently no effective cure. Brain-derived neurotrophic fa...

    Authors: Simone Tambaro, Sumonto Mitra, Ruchi Gera, Bengt Linderoth, Lars U. Wahlberg, Taher Darreh-Shori, Homira Behbahani, Per Nilsson and Maria Eriksdotter
    Citation: Alzheimer's Research & Therapy 2023 15:137
  23. Although hypertension is a critical risk factor for dementia, the association between primary aldosteronism (PA) and dementia has been scarcely reported. We aimed to investigate whether the risk of dementia in...

    Authors: Namki Hong, Kyoung Jin Kim, Min Heui Yu, Seong Ho Jeong, Seunghyun Lee, Jung Soo Lim and Yumie Rhee
    Citation: Alzheimer's Research & Therapy 2023 15:136
  24. Neuropsychiatric symptoms due to Alzheimer’s disease (AD) and mild cognitive impairment (MCI) can decrease quality of life for patients and increase caregiver burden. Better characterization of neuropsychiatri...

    Authors: Grace J. Goodwin, Stacey Moeller, Amy Nguyen, Jeffrey L. Cummings and Samantha E. John
    Citation: Alzheimer's Research & Therapy 2023 15:135
  25. Obstructive sleep apnoea (OSA) has a high prevalence in patients with Alzheimer’s disease (AD). Both conditions have been shown to be associated with lipid dysregulation. However, the relationship between OSA ...

    Authors: Farida Dakterzada, Iván D. Benítez, Adriano Targa, Anna Carnes, Montse Pujol, Mariona Jové, Olga Mínguez, Rafi Vaca, Manuel Sánchez-de-la-Torre, Ferran Barbé, Reinald Pamplona and Gerard Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2023 15:134
  26. Alzheimer’s dementia (AD) is associated with electroencephalography (EEG) abnormalities including in the power ratio of beta to theta frequencies. EEG studies in mild cognitive impairment (MCI) have been less ...

    Authors: Hamed Azami, Christoph Zrenner, Heather Brooks, Reza Zomorrodi, Daniel M. Blumberger, Corinne E. Fischer, Alastair Flint, Nathan Herrmann, Sanjeev Kumar, Krista Lanctôt, Linda Mah, Benoit H. Mulsant, Bruce G. Pollock and Tarek K. Rajji
    Citation: Alzheimer's Research & Therapy 2023 15:133
  27. Subjective cognitive decline (SCD) is a risk factor for Alzheimer’s disease (AD); however, the rates of cognitive decline are variable according to underlying pathologies and biomarker status. We conducted an ...

    Authors: Yun Jeong Hong, SeongHee Ho, Jee Hyang Jeong, Kee Hyung Park, SangYun Kim, Min Jeong Wang, Seong Hye Choi and Dong Won Yang
    Citation: Alzheimer's Research & Therapy 2023 15:132
  28. The paradigm shift towards earlier Alzheimer’s disease (AD) stages and personalized medicine creates new challenges for clinician-patient communication. We conducted a survey among European memory clinic profe...

    Authors: Heleen M. A. Hendriksen, Aniek M. van Gils, Argonde C. van Harten, Tobias Hartmann, Francesca Mangialasche, Anita Kamondi, Miia Kivipelto, Hanneke F. M. Rhodius-Meester, Ellen M. A. Smets, Wiesje M. van der Flier and Leonie N. C. Visser
    Citation: Alzheimer's Research & Therapy 2023 15:131
  29. There are few updated studies on the prevalence and management of Alzheimer’s disease (AD), which could be underdiagnosed or undertreated. The COVID-19 pandemic may have worsened the deficiencies in the diagno...

    Authors: Javier Olazarán, Cristóbal Carnero-Pardo, Juan Fortea, Pascual Sánchez-Juan, Guillermo García-Ribas, Félix Viñuela, Pablo Martínez-Lage and Mercè Boada
    Citation: Alzheimer's Research & Therapy 2023 15:130
  30. In order to utilize polygenic risk scores (PRSs) for Alzheimer’s disease (AD) in a meaningful way, influential factors (i.e. training set) and prediction across groups such as APOE e4 (APOE4) genotype as well as ...

    Authors: Hannah Stocker, Kira Trares, Léon Beyer, Laura Perna, Dan Rujescu, Bernd Holleczek, Konrad Beyreuther, Klaus Gerwert, Ben Schöttker and Hermann Brenner
    Citation: Alzheimer's Research & Therapy 2023 15:129
  31. With the emergence of disease-modifying Alzheimer’s treatments, timely detection of early-stage disease is more important than ever, as the treatment will not be indicated for later stages. Contemporary popula...

    Authors: Soeren Mattke, Hankyung Jun, Emily Chen, Ying Liu, Andrew Becker and Christopher Wallick
    Citation: Alzheimer's Research & Therapy 2023 15:128
  32. We aimed to quantify the identification of mild cognitive impairment and/or Alzheimer’s disease using olfactory-stimulated functional near-infrared spectroscopy using machine learning through a post hoc analys...

    Authors: Jaewon Kim, Hayeon Lee, Jinseok Lee, Sang Youl Rhee, Jae Il Shin, Seung Won Lee, Wonyoung Cho, Chanyang Min, Rosie Kwon, Jae Gwan Kim and Dong Keon Yon
    Citation: Alzheimer's Research & Therapy 2023 15:127
  33. Traumatic encephalopathy syndrome (TES) is a clinical phenotype sensitive but non-specific to underlying chronic traumatic encephalopathy (CTE) neuropathology. However, cognitive symptoms of TES overlap with A...

    Authors: Breton M. Asken, Jeremy A. Tanner, Leslie S. Gaynor, Lawren VandeVrede, William G. Mantyh, Kaitlin B. Casaletto, Adam M. Staffaroni, Corrina Fonseca, Ranjani Shankar, Harli Grant, Karen Smith, Argentina Lario Lago, Haiyan Xu, Renaud La Joie, Yann Cobigo, Howie Rosen…
    Citation: Alzheimer's Research & Therapy 2023 15:126
  34. People with intellectual disability (ID) without Down syndrome (DS) are presumed to be at higher risk of developing dementia due to their lower baseline cognitive reserve. We aimed to determine the prevalence ...

    Authors: Shintaro Takenoshita, Seishi Terada, Tomokazu Inoue, Taku Kurozumi, Norihito Yamada, Ryozo Kuwano and Shigeru Suemitsu
    Citation: Alzheimer's Research & Therapy 2023 15:125
  35. Alzheimer’s disease (AD) cerebrospinal fluid (CSF) core biomarkers (Aβ42/40 ratio, p-tau, and t-tau) provide high diagnostic accuracy, even at the earliest stage of disease. However, these markers do not fully...

    Authors: Silvia Paciotti, Anna Lidia Wojdała, Giovanni Bellomo, Andrea Toja, Elena Chipi, Sander R. Piersma, Thang V. Pham, Lorenzo Gaetani, Connie R. Jimenez, Lucilla Parnetti and Davide Chiasserini
    Citation: Alzheimer's Research & Therapy 2023 15:124
  36. Previous studies challenge the impact of obstructive sleep apnea (OSA) once patients are diagnosed with Alzheimer’s disease (AD). Nevertheless, OSA recognizably disrupts sleep, and relevant associations betwee...

    Authors: Adriano D. S. Targa, Iván D. Benítez, Anna Moncusí-Moix, Farida Dakterzada, Olga Minguez, Rafaela Vaca, Mireia Dalmases, Manuel Sanchez-de-la-Torre, Ferran Barbé and Gerard Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2023 15:123
  37. Alzheimer’s disease (AD) is a common age-related neurodegenerative disease in the central nervous system and is the primary cause of dementia. It is clinically characterized by the memory impairment, aphasia, ...

    Authors: Jia-jia Liu, Yun-fan Long, Peng Xu, Hai-dong Guo and Guo-hong Cui
    Citation: Alzheimer's Research & Therapy 2023 15:122
  38. Gene expression is dysregulated in Alzheimer’s disease (AD) patients, both in peripheral blood and post mortem brain. We investigated peripheral whole-blood gene (co)expression to determine molecular changes p...

    Authors: Emma S. Luckett, Magdalena Zielonka, Amine Kordjani, Jolien Schaeverbeke, Katarzyna Adamczuk, Steffi De Meyer, Koen Van Laere, Patrick Dupont, Isabelle Cleynen and Rik Vandenberghe
    Citation: Alzheimer's Research & Therapy 2023 15:121
  39. Emerging difficulty performing cognitively complex everyday tasks, or ‘instrumental activities of daily living’ (IADL) may be an early clinical sign of Alzheimer’s disease (AD). We aimed to investigate how cha...

    Authors: Mark A. Dubbelman, Kayden J. Mimmack, Emily H. Sprague, Rebecca E. Amariglio, Patrizia Vannini and Gad A. Marshall
    Citation: Alzheimer's Research & Therapy 2023 15:120
  40. The APOEε4-promoted risk of Alzheimer’s disease (AD) is lower in Black/African-Americans (B/AAs), compared to non-Hispanic whites (NHWs). Previous studies reported lower plasma apolipoprotein E (apoE) levels in N...

    Authors: Andreas Giannisis, Asma Al-Grety, Henrik Carlsson, Jennifer C. Howell, William T. Hu, Kim Kultima and Henrietta M. Nielsen
    Citation: Alzheimer's Research & Therapy 2023 15:119

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:160

  41. In the ongoing effort to discover treatments for Alzheimer’s disease (AD), there has been considerable focus on investigating the use of repurposed drug candidates. Mining of electronic health record data has ...

    Authors: Eric Hu, Tong Shu Li, Nathan E. Wineinger and Andrew I. Su
    Citation: Alzheimer's Research & Therapy 2023 15:118
  42. Donepezil is an approved therapy for the treatment of Alzheimer’s disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiolog...

    Authors: Patricia Diaz-Galvan, Giulia Lorenzon, Rosaleena Mohanty, Gustav Mårtensson, Enrica Cavedo, Simone Lista, Andrea Vergallo, Kejal Kantarci, Harald Hampel, Bruno Dubois, Michel J. Grothe, Daniel Ferreira and Eric Westman
    Citation: Alzheimer's Research & Therapy 2023 15:117

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:177

  43. Authors: Janne Marieke Herden, Peter Hermann, Isabel Schmidt, Kathrin Dittmar, Sezgi Canaslan, Luise Weglage, Sabine Nuhn, Corinna Volpers, Astrid Schlung, Stefan Goebel, Fabian Kück, Anna Villar‑Piqué, Christian Schmidt, Dirk Wedekind and Inga Zerr
    Citation: Alzheimer's Research & Therapy 2023 15:116

    The original article was published in Alzheimer's Research & Therapy 2023 15:106

  44. Alzheimer’s disease (AD) is caused by many intertwining pathologies involving metabolic aberrations. Patients with metabolic syndrome (MetS) generally show hyperglycemia and dyslipidemia, which can lead to the...

    Authors: Monika Renuka Sanotra, Shu-Huei Kao, Ching-Kuo Lee, Chun-Hsien Hsu, Wen-Chung Huang, Tsuei-Chuan Chang, Fang-Yu Tu, I-Uen Hsu and Yung-Feng Lin
    Citation: Alzheimer's Research & Therapy 2023 15:115
  45. Neuropsychiatric symptoms (NPS) are a core feature of most neurodegenerative and cerebrovascular diseases. White matter hyperintensities and brain atrophy have been implicated in NPS. We aimed to investigate t...

    Authors: Miracle Ozzoude, Brenda Varriano, Derek Beaton, Joel Ramirez, Sabrina Adamo, Melissa F. Holmes, Christopher J. M. Scott, Fuqiang Gao, Kelly M. Sunderland, Paula McLaughlin, Maged Goubran, Donna Kwan, Angela Roberts, Robert Bartha, Sean Symons, Brian Tan…
    Citation: Alzheimer's Research & Therapy 2023 15:114
  46. Genome-wide association studies (GWAS) have indicated moderate genetic overlap between Alzheimer’s disease (AD) and related dementias (ADRD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS), n...

    Authors: Michael Wainberg, Shea J. Andrews and Shreejoy J. Tripathy
    Citation: Alzheimer's Research & Therapy 2023 15:113
  47. Alzheimer’s disease is a neurodegenerative disorder associated with the abnormal deposition of pathological processes, such as amyloid-ß and tau, which produces nonlinear changes in the functional connectivity...

    Authors: Mite Mijalkov, Dániel Veréb, Anna Canal-Garcia, Thomas Hinault, Giovanni Volpe and Joana B. Pereira
    Citation: Alzheimer's Research & Therapy 2023 15:112
  48. Dementia, one of the fastest-growing public health problems, is a cognitive disorder known to increase in prevalence as age increases. Several approaches had been used to predict dementia, especially in buildi...

    Authors: Michael Adebisi Fayemiwo, Toluwase Ayobami Olowookere, Oluwabunmi Omobolanle Olaniyan, Theresa Omolayo Ojewumi, Idowu Sunday Oyetade, Shannon Freeman and Piper Jackson
    Citation: Alzheimer's Research & Therapy 2023 15:111